Better Pharma Processes LogoBetter Pharma Processes for Small Molecule Drugs
major pharmaceutical drugs, small molecule drugs
Better Pharma Processes provides process chemistry consulting and training
Pharmaceutical Process Chemistry for Synthesis

""
by Peter J. Harrington, Ph.D.

View sections inside book (PDF):

 

Welcome!

GOOD SCIENCE IS GOOD BUSINESS

Better Pharma Processes provides consulting and training in the field of pharmaceutical process chemistry.  Please read excerpts from our newest book at left, "Pharmaceutical Process Chemistry for Synthesis: Rethinking the Routes to Scale-Up".

Our mission is to provide:

  • Timely, innovative, practical, and well-integrated solutions to synthetic problems

These problems are encountered at any stage during the development of a pharmaceutical manufacturing process. They run the gamut from sourcing starting materials to API polymorph screening. 

We accomplish this by:

  • Timely communication of insights gained from a rigorous and multidisciplinary review of the problem(s)
  • Followed by transmission of proposals with full supporting documentation

We communicate via:

  • One or more confidential avenues, tailored to meet your needs

These avenues may include online communication, teleconferencing, face-to-face conferencing at a site of your choosing, or a combination of methods that work for you.

We utilize a “no-stone-left-unturned” approach:

This approach is illustrated for the process chemistry of the top-selling small molecule drugs in the US (2007-2008), in our recently released book:

  • "Pharmaceutical Process Chemistry for Synthesis:
    Rethinking the Routes to Scale-Up"     (please see left column)

In line with this mission, we also provide:

  • Well-organized, focused, and audience-specific training
  • and
  • Fully documented current reviews of the process chemistry of top-selling drugs

 

© 2010 better pharma processes; all rights reserved


Better Pharma Processes, owned by Peter Harrington, PhD, provides consulting and training in the field of pharmaceutical process chemistry. 
Dr. Harrington's newest book, "Pharmaceutical Process Chemistry for Synthesis: Rethinking the Routes to Scale-Up", describes the process chemistry involved in several popular small-molecule drugs, including abilify®, celebrex®, crestor®, cymbalta®, flonase®, levaquin®, topamax®, valtrex®, and zyprexa®.